In July 2019, Amgen’s Kanjinti (trastuzumab biosimilar) and Mvasi (bevacizumab biosimilar) were the first monoclonal antibody (MAb) biosimilars launched in the United States. Between mid-…
MARKET OUTLOOKNon-small-cell lung cancer (NSCLC) has a high incidence and a large number of premium-priced therapies, which results in a significant financial burden on payers. Costs are set to…
The launch of several novel therapies, as well as multiple label expansions of premium-priced agents, will fuel significant growth of the non-Hodgkin’s lymphoma (NHL) therapy market over the ten-…
DRG Epidemiology’s coverage of membranous nephropathy (MN) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France,…
DRG Epidemiology’s coverage of membraneous nephropathy (MN) comprises epidemiological estimates of key patient populations in 45 countries. We report both the incidence and prevalence of MN for…
DRG Epidemiology’s coverage of membranous nephropathy (MN) comprises epidemiological estimates of key patient populations in 45 countries. We report both the incidence and the prevalence of MN…
DRG Epidemiology’s coverage of membranous nephropathy (MN) comprises epidemiological estimates of key patient populations in 45 countries. We report both the incidence and the prevalence of MN…
DRG Epidemiology’s coverage of membranous nephropathy (MN) comprises epidemiological estimates of key patient populations in 45 countries. We report both the incidence and the prevalence of MN…
DRG Epidemiology’s coverage of menbranous nephropathy (MN) comprises epidemiological estimates of key patient populations in 45 countries. We report both the incidence and the prevalence of MN…
DRG Epidemiology’s coverage of IgA nephropathy (IgAN) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany…
The maturing yet highly lucrative market for multiple sclerosis (MS) disease-modifying therapies (DMTs) will continue to fragment as new entrants further shift the complicated treatment algorithm…
Market Outlook Treatment for recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) has remained relatively unchanged in the past ten years, and Erbitux-based regimens…
DRG Epidemiology’s coverage of Huntington’s disease (HD) comprises epidemiological estimates of key patient populations in 12 major mature pharmaceutical markets (Austria, Belgium, Czech…
DRG Epidemiology’s coverage of Huntington’s disease (HD) comprises epidemiological estimates of key patient populations in seven emerging pharmaceutical markets (Brazil, Russia, India, China,…
DRG Epidemiology’s coverage of Huntington’s disease (HD) comprises epidemiological estimates of key patient populations in the Americas (Argentina, Canada, Chile, Colombia, and Peru). We report…